Tanke Biosciences Corporation
TNBI · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $8 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $1 | $0 |
| Gross Profit | $8 | -$1 | -$1 | -$0 |
| % Margin | 93% | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $69 | $90 | $43 | $22 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $69 | $90 | $43 | $22 |
| Operating Income | -$61 | -$90 | -$44 | -$23 |
| % Margin | -729.2% | – | – | – |
| Other Income/Exp. Net | -$4 | -$9 | -$14 | $0 |
| Pre-Tax Income | -$66 | -$99 | -$58 | -$23 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$66 | -$99 | -$58 | -$23 |
| % Margin | -781.1% | – | – | – |
| EPS | -0.003 | -0.004 | -0.002 | -0.001 |
| % Growth | 33.3% | -69.6% | -130% | – |
| EPS Diluted | -0.003 | -0.004 | -0.002 | -0.001 |
| Weighted Avg Shares Out | 25,464 | 25,464 | 25,464 | 22,289 |
| Weighted Avg Shares Out Dil | 25,464 | 25,464 | 25,464 | 22,289 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $9 | $1 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$63 | -$90 | -$43 | -$22 |
| % Margin | -742.4% | – | – | – |